Janice Dutcher
New York, NYNPI 1730242124
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $762,328 of the $762,938 with a category attached, or 99.9%. 10 manufacturers reported payments, led by Daiichi Sankyo Inc. at 34.2% of the total.
Across 160 payments — averaging $4768.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$261K
- E.r. Squibb & Sons, L.L.C.$206K
- Merck$174K
- Eisai Inc.$95K
- Amgen$17K
- Iovance Biotherapeutics, Inc.$8K
- plus $4K from 4 others
Across 50 payments — averaging $2801.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$140K
What the payments were for
- Consulting fees$762,328100%
- Travel & lodging$4820%
- Food & beverage$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 18 | $260,625 |
| E.r. Squibb & Sons, L.L.C. | 52 | $205,823 |
| Merck | 52 | $173,958 |
| Eisai Inc. | 22 | $94,513 |
| Amgen | 9 | $16,538 |
| Iovance Biotherapeutics, Inc. | 3 | $7,875 |
| AstraZeneca | 1 | $3,000 |
| Clinigen, Inc. | 1 | $480 |
| Bristol Myers Squibb | 1 | $96 |
| Beone Medicines USA, Inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.